The global weight-loss medication market has reached another major milestone after China approved its first oral GLP-1 drug for weight management, giving American pharmaceutical company Eli Lilly an early advantage in one of the world’s largest potential obesity treatment markets.
The newly approved medication, orforglipron, will be marketed in China under the name Muyouda and offers patients an alternative to existing injectable weight-loss treatments. The approval comes as concerns over rising obesity rates grow, with projections suggesting that as many as 630 million Chinese adults could be overweight or obese by 2050.
Highlights
- China has approved its first oral GLP-1 medication for weight management.
- Eli Lilly’s orforglipron will be sold under the name Muyouda.
- The once-daily tablet is intended for adults with obesity or overweight alongside at least one weight-related health condition.
- Eli Lilly has secured approval ahead of rival pharmaceutical company Novo Nordisk.
- China could have 630 million overweight or obese adults by 2050, according to a 2025 study.
Main Story
China Approves First Oral GLP-1 Weight-Loss Medication
China has officially approved its first orally administered GLP-1 medication for weight management, marking a significant development in the country’s growing pharmaceutical industry.
The National Medical Products Administration (NMPA) announced on Thursday, November 12, 2026, that it had authorised American pharmaceutical giant Eli Lilly to market its orforglipron tablets.
The medication will be sold locally under the brand name Muyouda and is intended for adults living with obesity or those who are overweight and have at least one weight-related medical condition.
The approval also gives patients another option beyond injectable treatments, which have dominated the GLP-1 weight-management market.
According to the approval announcement, the medication is intended to be used alongside dietary changes and increased physical activity.
How the New Weight-Loss Pill Works
GLP-1 medications work by imitating the activity of a naturally occurring hormone involved in appetite regulation and blood sugar control.
By activating GLP-1 receptors, these treatments can help reduce hunger, increase feelings of fullness and support better blood sugar regulation.
Unlike traditional GLP-1 injections, orforglipron is taken orally once a day.
This could make it an attractive alternative for patients who prefer tablets to regular injections.
However, like other prescription weight-management medicines, it is not suitable for everyone and should only be used under appropriate medical supervision.
Eli Lilly Beats Novo Nordisk in China’s Drug Market
The approval represents an important competitive milestone for Eli Lilly, which has moved ahead of Danish pharmaceutical company Novo Nordisk in securing approval for an oral GLP-1 weight-loss treatment in China.
Novo Nordisk manufactures popular weight-management medication Wegovy and has also been pursuing opportunities in the oral obesity treatment market.
Although its application for an oral version of Wegovy has been accepted by Chinese regulators, it had not received approval for that indication by November 12.
Meanwhile, injectable GLP-1 treatments from Eli Lilly, Novo Nordisk and Chinese pharmaceutical company Innovent are already available in the country.
China Faces Growing Obesity Concerns
The approval comes at a time when China is preparing for a significant increase in obesity-related health challenges.
A 2025 study published in medical journal The Lancet projected that the number of Chinese adults who are overweight or obese could reach approximately 630 million by 2050.
The country’s National Health Commission has also warned that around 65 per cent of its population could fall into the overweight or obese category by 2030.
These projections have created growing demand for medical interventions, with pharmaceutical companies increasingly investing in treatments targeting weight management.
What the Approval Means for the Future of Weight Management
The introduction of an oral GLP-1 treatment could change how patients access obesity medication, particularly those who are uncomfortable with injections.
However, the approval does not mean the medication is appropriate for everyone seeking to lose weight.
Medical professionals generally assess a patient’s health condition, medical history and potential risks before prescribing weight-management medication.
Eli Lilly is preparing to introduce the treatment through authorised healthcare and pharmaceutical institutions, although pricing and the precise commercial rollout arrangements have not been fully disclosed.
With more pharmaceutical companies working on oral alternatives, the competition between drugmakers could reshape the future of obesity treatment.
As pharmaceutical companies race to make weight management treatments more accessible, China’s latest approval signals a growing shift towards oral medication. Could weight-loss tablets become the next major development in the global healthcare industry?
